ST. LOUIS, April 5 /PRNewswire-FirstCall/ -- GenoMed Inc. (“the Company” or “GenoMed”) , a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it has partnered with Dressage.com, a widely respected website in the equestrian community, to publicize its free trial for West Nile virus encephalitis in horses.
GenoMed has been using safe, already existing pills to treat West Nile virus encephalitis in humans for the past 3 summers, and in birds for the past 2 summers. In humans, GenoMed’s treatment approach is running better than an 85% success rate (19 patients out of 22). The first 8 patients were published in a peer-reviewed medical journal in 2004. GenoMed’s treatment has been used in a smaller number of birds (only 12), with a 50% save rate. This is quite good, since the disease is uniformly fatal, and the birds are found on their last legs, so to speak.
Said Kyra Beth Houston, Editor of Dressage.com, “For years, veterinarians have been treating WNV in horses with non-steroidal anti-inflammatory drugs, in line with GenoMed’s treatment approach. We’re happy to help get the word out about GenoMed’s clinical trial. Although a reliable WNV vaccine exists for horses, it’s always good to have a back-up treatment in case the horse doesn’t get vaccinated for some reason. And our readers will be relieved to know that they can join GenoMed’s trial if they come down with WNV themselves.”
Added David Moskowitz, MD, GenoMed’s CEO and Chief Medical Officer, “We think that the animals (and humans) who get into trouble from the virus do so because they over-react to it. If anything, their immune response is too strong, not too weak, as is still claimed for humans. This explains why most of the people who die of WNV were so healthy beforehand.”
To enroll in GenoMed’s free clinical trial, which uses existing, safe medication already present in every drug store, just go to http://www.genomed.com and click on the link for the West Nile virus trial. GenoMed’s approach may work against most viruses, including avian influenza (“bird flu”).
About GenoMed
GenoMed has found what it believes to be the “master” disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of end-stage emphysema; and begin to see success in treating cancer and autoimmune diseases. GenoMed’s broad-spectrum anti-viral approach was specifically mentioned in BioShield II (see Section 2151 of Senate bill S. 975). GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians -- breast, colon, lung, ovarian, pancreatic, and prostate -- and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed Inc.
CONTACT: David Moskowitz MD of GenoMed, Inc., +1-314-983-9938,dwmoskowitz@genomed.com , or Kyra Beth Houston, CEO of Dressage un Ltd -Dressage.com , +1-918-234-1042, Ky@Dressage.com
Web site: http://www.genomed.com/
